Diabetes, treatment peroxisome proliferator receptor

Peroxisome Proliferator activated receptor (PPAR-GAMMA-2) Insulin Variation of insulin efficacy in the treatment of diabetes (93) Susceptibility to type II diabetes (93)... 

Several fluorine-containing drugs are currently in development for the treatment of diabetes. These are peroxisome proliferator-activated nuclear receptor (PPAR) agonists, aldose reductase, and dipeptidylpeptidase IV (DPP-IV) inhibitors. 

Rosiglitazone 9, an agonist of peroxisome proliferator activated receptor-y (PPARy), is a recently introduced antihyperglycemic thiazolidinedione effective in the treatment of noninsulin dependant diabetes mellitus (type II diabetes). A seven-step synthesis was developed (Scheme 3), which utilised supported reagents in combination with in-line SPE purifications. The introduction of the pyridine moiety provided a convenient molecular handle by which to purify the molecule throughout the synthesis. Notably, the overall yield (46%) for this synthesis was higher than the yield reported in the initial shorter solution-phase synthesis (31%). ... 

Henke, B. R. Peroxisome proliferator-activated receptor alpha/ gamma dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 2004, 47(17), 4118-4127. 

Peroxisome Proliferator-Activated Receptor 7 Modulation for the Treatment of Type 2 Diabetes... 

Peroxisome proliferator-activated receptors are ligand-activated receptors which regulate a number of genes involved in nutrient metabolism and energy homeostasis, and thus have served as drug targets for the treatment of metabolic diseases. Anne Reifel Miller and Alan M. Warshawsky review peroxisome proliferator-activated receptor y modulation for the treatment of type 2 diabetes. 

---